Pushing Ahead With New Treatments for Nonmetastatic Castration-Resistant Prostate Cancer
Updates and Insights on the Medical Science of Prostate Cancer (Transcript)
Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN - European Urology
ASCO 2020: Final Survival Results from SPARTAN, A Phase III Study of Apalutamide versus Placebo in Patients with Nonmetastatic Castration-Resistant Prostate Cancer
ASCO 2020: Final Survival Results from SPARTAN, A Phase III Study of Apalutamide versus Placebo in Patients with Nonmetastatic Castration-Resistant Prostate Cancer
Case 1: SPARTAN Trial for Apalutamide in nmCRPC
The SPARTAN Study: A Pilot Study to Assess the Safety and Efficacy of an Investigational NRTI- and RTV-Sparing Regimen of Atazanavir (ATV) Experimental Dose of 300mg BID plus Raltegravir (RAL) 400mg BID (
Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer - Annals of Oncology
Final Survival Results From SPARTAN, a Phase 3 Study of Apalutamide Versus Placebo in Patients With Nonmetastatic Castration-Resistant Prostate Cancer - Beyond the Abstract
ASCO 2020: Final Survival Results from SPARTAN, A Phase III Study of Apalutamide versus Placebo in Patients with Nonmetastatic Castration-Resistant Prostate Cancer
ESMO 2019: Updated Results from the Phase 3 SPARTAN Study, Apalutamide and Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer
nmCRPC - Optimal Care in Prostate Cancer - Text Module - Therapeutic Strategies in Prostate Cancer - Oncology - Clinical Care Options
Treatment and trials in non-metastatic castration-resistant prostate cancer | Nature Reviews Urology
nmCRPC - Optimal Care in Prostate Cancer - Text Module - Therapeutic Strategies in Prostate Cancer - Oncology - Clinical Care Options
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer | NEJM
ARV-Trials.com
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer | NEJM
ASCO 2019: Efficacy of Apalutamide plus Ongoing Androgen Deprivation Therapy in Patients with Nonmetastatic Castration-Resistant Prostate Cancer and Baseline Comorbidities
Metastatic Castration-Sensitive Prostate Cancer: Optimizing Patient Selection and Treatment | American Society of Clinical Oncology Educational Book
Final Analysis of SPARTAN Study
Beyond the Androgen Receptor: The Sequence, the Mutants, and New Avengers in the Treatment of Castrate-Resistant Metastatic Prostate Cancer | American Society of Clinical Oncology Educational Book
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer | NEJM
SPARTAN: quality of life related to the use of apalutamide in patients with castration-resistant non-metastatic prostate cancer - Onco Americas
ASCO 2020: Molecular Determinants of PSA Kinetics and Clinical Response to Apalutamide in Patients with nmCRPC in SPARTAN
ASCO GU 2022: Association between PROs and Changes in PSA in Patients with Advanced Prostate Cancer Treated with Apalutamide in the SPARTAN and TITAN Studies
Pivotal Trials Efficacy Data | For HCPs | REYVOW® (lasmiditan)
Apalutamide and Overall Survival in Prostate Cancer - ScienceDirect
